(Hong Kong, 7 October 2021) – Hong Kong Science and Technology Parks Corporation (HKSTP) announced that leading global biotech company Miltenyi Biotec B.V. & Co. KG (Miltenyi Biotec) today opened Miltenyi Biotec Hong Kong Limited (Miltenyi Biotec Hong Kong) at Hong Kong Science Park. The Hong Kong subsidiary serves as Miltenyi Biotec’s regional research and development (R&D) centre to transfer its state-of-the-art technologies, products and services in cell and gene therapy to Hong Kong, the Greater Bay Area and APAC region.
Headquartered in Germany, Miltenyi Biotec has accumulated 30 years of experience in empowering the advancement of biomedical research and enabling cell and gene therapy. The company offers more than 17,000 products for research and clinical applications. Cellular therapeutics manufactured using Miltenyi Biotec technologies are used to treat about 6,000 patients annually.
Leveraging Hong Kong Science Park’s world-class infrastructure and thriving ecosystem, Miltenyi Biotec Hong Kong will make Miltenyi Biotec’s innovative solutions for cell and gene therapy available to patients and customers in China and APAC region. Mr Ken Ooi, General Manager of Miltenyi Biotec, APAC & China, said: “We believe in the huge potential biomedical research and cellular therapies have in China and APAC region. There are many excellent scientific institutions and brilliant innovators that could achieve outstanding things using our solutions.”
Prof. John Kao, Head of Institute for Translational Research, HKSTP, said: “We are delighted to welcome Miltenyi Biotec Hong Kong to our growing biotech community at Hong Kong Science Park. HKSTP has recently launched the Institute for Translational Research to spearhead the translation of biomedical technologies to benefit the public. With the latest addition of Miltenyi Biotec Hong Kong in our I&T ecosystem, we foresee unlimited opportunities for collaborations and co-creations with synergies for translational research and development.”
